文献速递系统性红斑狼疮类风湿关节炎血管炎

胞葬作用及其在风湿性疾病中的作用

Efferocytosis and Its Role in Rheumatic Diseases.
PubMed 文献 · Arthritis Rheumatol · 2025-08-13

本文综述胞葬作用(吞噬细胞清除凋亡细胞)的多步骤过程及其在常见风湿性疾病中的意义,重点讨论异常胞葬作用在系统性红斑狼疮发生发展中的作用,并总结类风湿关节炎、干燥病、抗中性粒细胞胞质抗体相关血管炎、系统性硬化症、抗磷脂综合征、痛风和骨关节炎中的研究进展,指出针对胞葬作用具有治疗潜力但多数策略仍处于临床前阶段。

要点

  • 胞葬作用清除凋亡细胞,防止其继发性坏死,产生抗炎介质并促进炎症消退。
  • 适当的胞葬作用对维持免疫耐受和防止自身抗原暴露至关重要,而胞葬作用缺陷与多种风湿性疾病的发生相关。
  • 针对胞葬作用的治疗策略多数仍处于临床前阶段,一项研究凋亡细胞输注治疗难治性类风湿关节炎的临床试验已被提出。

核心结论

  • 尽管免疫系统的复杂性和胞葬作用相关分子的多效性带来挑战,越来越多的证据支持胞葬作用作为风湿性疾病潜在治疗靶点。

研究设计与样本

  • 本文为综述,回顾胞葬作用的过程及其在常见风湿性疾病中的意义,重点讨论系统性红斑狼疮,并总结类风湿关节炎、干燥病、抗中性粒细胞胞质抗体相关血管炎、系统性硬化症、抗磷脂综合征、痛风和骨关节炎中的研究进展。

主要发现

  • 胞葬作用是多步骤过程,包括识别、结合、内化和降解凋亡细胞。
  • 胞葬作用清除凋亡细胞,防止其继发性坏死,产生抗炎介质并促进炎症消退。
  • 适当的胞葬作用对维持免疫耐受和防止自身抗原暴露至关重要,而胞葬作用缺陷与多种风湿性疾病的发生相关。
  • 一项研究凋亡细胞输注治疗难治性类风湿关节炎的临床试验已被提出,突出靶向胞葬作用的治疗潜力。
  • 新兴策略如肝X受体/过氧化物酶体增殖物激活受体激动剂、含DNase纳米颗粒、Tyro3、Axl和Mer受体激动剂及抗CD47抗体显示出前景,但多数仍处于临床前阶段。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Efferocytosis, the process through which phagocytes clear apoptotic cells (ACs), has rapidly emerged as an expanding field of research. This multistep process involves recognizing, binding, internalizing, and degrading ACs. Efferocytosis clears ACs, preventing their secondary necrosis, generating anti-inflammatory mediators, and promoting the resolution of inflammation. Appropriate efferocytosis is essential for preserving immune tolerance and preventing exposure to self-antigens, whereas defective efferocytosis is linked to the onset of various rheumatic diseases. Here, we review the process of efferocytosis and its implications in common rheumatic diseases. This review focuses on the role of abnormal efferocytosis in the development and progression of systemic lupus erythematosus. We also summarize recent advances in understanding efferocytosis in other rheumatic diseases, including rheumatoid arthritis (RA), Sjögren disease, antineutrophil cytoplasmic antibody-associated vasculitis, systemic sclerosis, antiphospholipid syndrome, gout, and osteoarthritis. Notably, a clinical trial investigating AC infusion for refractory RA has been proposed, highlighting the therapeutic potential of targeting efferocytosis. In addition, emerging strategies-such as liver X receptor/peroxisome proliferator-activated receptor agonists; DNase-containing nanoparticles; Tyro3, Axl, and Mer receptor agonists; and anti-CD47 antibodies-show promise, although most remain at the preclinical stage. Despite the challenges posed by the immune system's complexity and the pleiotropic functions of efferocytosis-related molecules, growing evidence supports efferocytosis as a potential therapeutic target in rheumatic diseases.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Tang X, Peng Y, Jiang Z, et al. Efferocytosis and Its Role in Rheumatic Diseases. Arthritis Rheumatol. 2025. PMID: 40452369. doi:10.1002/art.43268

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。